The Hemodynamic Response to Prolonged Dobutamine Infusion
Information source: Hadassah Medical Organization
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy; Heart Failure
Intervention: 3 hours intravenous dobutamine (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Hadassah Medical Organization
Summary
A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is
thought to play a major role in the pathogenesis of diseases such as congestive heart
failure. However, currently, there is no in vivo model that will enable us to measure
desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.
Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1
adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic
responses to dobutamine over time.
Clinical Details
Study design: Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label
Primary outcome: Heart rate
Secondary outcome: Systolic blood pressure
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- healthy subjects
Exclusion Criteria:
- consumption of any medications during the 2 weeks prior to the study
- history of chest pain or tachycardia
Locations and Contacts
Hadassah University Hospital, Jerusalem 91120, Israel; Recruiting Mordechai Muszkat, MD, Phone: 972-2-6777335, Email: muszkatm@hadassah.org.il Mordechai Muszkat, MD, Principal Investigator
Additional Information
Related publications: Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4.
Starting date: January 2010
Last updated: July 3, 2011
|